Entering text into the input field will update the search result below

Regeneron maintained as overweight at Piper but concern over Eylea outlook

Mar. 03, 2022 11:24 AM ETRegeneron Pharmaceuticals, Inc. (REGN) StockRHHBYBy: Jonathan Block, SA News Editor

Wall Street Sign

ozgurdonmaz/E+ via Getty Images

  • Although Piper Sandler is maintaining an outperform rating for Regeneron Pharmaceuticals (REGN -0.9%), a new survey is providing concern for the competitive outlook for the company age-related macular degeneration ("AMD") treatment Eylea (aflibercept).
  • The firm

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

About REGN

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
Regeneron Pharmaceuticals, Inc.
Vertex Pharmaceuticals Incorporated
Gilead Sciences, Inc.
Seagen Inc.
Biogen Inc.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.